第 1 到 101 筆結果,共 101 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2023 | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma | BANG-BIN CHEN ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH ; TSUNG-HAO LIU ; YING-CHUN SHEN ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | European radiology | 20 | 13 | |
2 | 2023 | Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancer | JHE-CYUAN GUO ; Hsu, Chia-Lang; MIN-SHU HSIEH ; CHIA-CHI LIN ; TA-CHEN HUANG ; HUNG-YANG KUO ; YU-YUN SHAO ; CHIH-HUNG HSU | Thoracic cancer | 0 | 0 | |
3 | 2023 | Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study | YI-HSIN LIANG ; KUO-HSING CHEN ; YU-YUN SHAO | Cancer medicine | 0 | 0 | |
4 | 2023 | Another prognostic marker for hepatocellular carcinoma | YU-YUN SHAO | Hepatology international | 0 | 0 | |
5 | 2023 | Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants | YU-YUN SHAO ; Ho, Ching-Liang; Chang, Cheng-Shyong; Chang, Chia-Lun; JEN-KUANG LEE ; HUNG-JU LIN ; Hsiao, Hui-Hua; Chao, Ta-Chung; Lin, Ching-Yeh; Liaw, Chuang-Chi | Acta Cardiologica Sinica | 1 | 1 | |
6 | 2022 | Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment | Chen, Ching-Tso; Feng, Yin-Hsun; Yen, Chia-Jui; Chen, San-Chi; Lin, Yun-Tzu; LI-CHUN LU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | Hepatology international | 14 | 14 | |
7 | 2022 | Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study | Chen, Ching-Tso; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | Anticancer research | 0 | 0 | |
8 | 2022 | Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma | YU-YUN SHAO ; Chen, Pai-Sheng; LIANG-IN LIN ; Lee, Bin-Shyun; Ling, Andrew; ANN-LII CHENG ; CHIUN HSU ; DA-LIANG OU | British journal of cancer | 10 | 10 | |
9 | 2022 | Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma | YU-YUN SHAO ; HUNG-YANG KUO ; YUNG-MING JENG ; YAO-MING WU ; HSIU-PO WANG ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | BMC cancer | 3 | 3 | |
10 | 2022 | Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma | Lee, Jan-Mou; Hung, Yi-Ping; Chou, Kai-Yuan; Lee, Cheng-Yun; Lin, Shian-Ren; Tsai, Ya-Han; Lai, Wan-Yu; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; Chao, Yee | Frontiers in medicine | 2 | 2 | |
11 | 2022 | Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma | YU-YUN SHAO ; Hsu, Hung-Wei; Wo, Rita Robin; Wang, Han-Yu; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology | 3 | 3 | |
12 | 2022 | ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis | LI-CHUN LU ; Deantonio, Cecilia; Palu, Cintia C; Lee, Yi-Hsuan; Mitchell, Laura S; Cowan, Marianne; Corser, Matthew; Sherry, Lorcan; ANN-LII CHENG ; Quaratino, Sonia; YU-YUN SHAO ; Sainson, Richard C A; CHIH-HUNG HSU | Oncology (Switzerland) | 1 | 0 | |
13 | 2022 | Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety | YU-YUN SHAO ; Feng Y.-H.; Yen C.-J.; Yang T.-S.; YING-CHUN SHEN ; Chao Y.; Chen J.-S.; Su C.-Y.; Chen W.-J.; Hsiang H.-L.; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 3 | 4 | |
14 | 2022 | Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study | Chen S.-C.; Huang Y.-H.; Chen M.-H.; Hung Y.-P.; Lee R.-C.; YU-YUN SHAO ; Chao Y. | BMC Cancer | 14 | 12 | |
15 | 2021 | Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma | Chen, Ching-Tso; TSUNG-HAO LIU ; YU-YUN SHAO ; KAO-LANG LIU ; PO-CHIN LIANG ; ZHONG-ZHE LIN | International journal of molecular sciences | 17 | 8 | |
16 | 2021 | Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials | BANG-BIN CHEN ; ZHONG-ZHE LIN ; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Cancers | 4 | 3 | |
17 | 2021 | Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma | BANG-BIN CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Diagnostics (Basel, Switzerland) | 7 | 7 | |
18 | 2021 | Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | YU-YUN SHAO ; Wang, Shen-Yung; Lin, Shi-Ming; Chen, Kuan-Yang; Tseng, Jeng-Hwei; MING-CHIH HO ; Lee, Rheun-Chuan; PO-CHIN LIANG ; Liao, Li-Ying; KAI-WEN HUANG ; Hu, Jui-Ting; JA-DER LIANG ; Kee, Kwong-Ming; Lin, Chih-Lin; Wang, Chung-Kwe; Lu, Sheng-Nan; Wang, Jing-Houng; Lee, Wei-Chen; CHIEN-HUNG CHEN ; CHUN-JEN LIU ; Huang, Yi-Hsiang; Wang, Chia-Chi; Wang, Tsang-En; Chuang, Po-Heng; Dai, Chia-Yen; CHIUN HSU ; Chen, San-Chi; Hsieh, Chia-Hsun | Journal of the Formosan Medical Association | 67 | 65 | |
19 | 2021 | Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma | CHIH-HORNG WU ; PO-CHIN LIANG ; CHIH-HUNG HSU ; Chang, Fang-Tsu; YU-YUN SHAO ; TIFFANY TING-FANG SHIH | Journal of the Formosan Medical Association = Taiwan yi zhi | 21 | 17 | |
20 | 2021 | Reply to letter to the editor: Low skeletal muscle mass are predictive factors of survival for advanced hepatocellular carcinoma | CHIH-HORNG WU ; YU-YUN SHAO ; TIFFANY TING-FANG SHIH | Journal of the Formosan Medical Association = Taiwan yi zhi | 0 | 0 | |
21 | 2021 | Impact of expanded strong opioid availability on opioid prescription patterns in patients with cancer: A population-wide cohort study in Taiwan | Wu T.-C.; CHIH-HUNG HSU ; WEI-ZEN SUN ; Chen H.-M.; CHIH-PENG LIN ; YU-YUN SHAO | The Lancet Regional Health - Western Pacific | 3 | 3 | |
22 | 2021 | Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy | YING-CHUN SHEN ; Yeh C.-P.; YUNG-MING JENG ; CHIUN HSU ; CHIH-HUNG HSU ; ZHONG-ZHE LIN ; YU-YUN SHAO ; LI-CHUN LU ; TSUNG-HAO LIU ; CHIEN-HUNG CHEN ; ANN-LII CHENG | Cancers | 2 | 2 | |
23 | 2021 | Correspondence to: Management of venous thromboembolisms: Part II. The consensus for pulmonary embolism and updates | YU-YUN SHAO ; HUNG-JU LIN | Acta Cardiologica Sinica | 2 | 2 | |
24 | 2021 | Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma | Hung Y.-P.; YU-YUN SHAO ; Lee J.-M.; CHIUN HSU ; CHIH-HUNG HSU ; Yang M.-H.; Chao Y. | Journal of the Chinese Medical Association | 10 | 9 | |
25 | 2021 | An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma | YU-YUN SHAO ; ANN-LII CHENG ; CHIH-HUNG HSU | Oncologist | 9 | 5 | |
26 | 2021 | It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade | TSUNG-HAO LIU ; YU-YUN SHAO ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 7 | 9 | |
27 | 2021 | The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma | Hung Y.-P.; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; Lee J.-M.; Yang M.-H.; Chao Y. | Journal of the Formosan Medical Association | 4 | 4 | |
28 | 2021 | Solving the deficit of cancer pain management skills by education programs | YU-YUN SHAO ; WEN-YING LIN ; CHIH-PENG LIN ; LI-CHUN LU ; CHIH-HUNG HSU | Supportive Care in Cancer | 2 | 2 | |
29 | 2021 | Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma | YU-YUN SHAO ; Sun, Nai-Yun; YUNG-MING JENG ; YAO-MING WU ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | Cells | 3 | 2 | |
30 | 2020 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy | ZHONG-ZHE LIN ; BANG-BIN CHEN ; Hung, Yi-Ping; HUANG, PO-HSIANG ; Ying-Chun Shen ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG ; Lee, Rheun-Chuan; Chao, Yee; CHIUN HSU | Oncologist | 12 | 10 | |
31 | 2020 | Satisfaction with pain management and impact of pain on quality of life in cancer patients | Johnson Lin; Ruey‐Kuen Hsieh; Jen‐Shi Chen; Kuan‐Der Lee; Kun‐Ming Rau; YU-YUN SHAO ; Yung‐Chuan Sung; Su‐Peng Yeh; Cheng‐Shyong Chang; Ta‐Chih Liu; Ming‐Fang Wu; Ming‐Yang Lee; Ming‐Sun Yu; Chia‐Jui Yen; Pang‐Yu Lai; Wen‐Li Hwang; Tzeon‐Jye Chiou | Asia-Pacific Journal of Clinical Oncology | 11 | 2 | |
32 | 2019 | Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors | JHE-CYUAN GUO ; CHIA-CHI LIN ; Lin, Chen Yuan; MIN-SHU HSIEH ; HUNG-YANG KUO ; Lien, Ming Yu; YU-YUN SHAO ; Ta-Chen Huang ; CHIH-HUNG HSU | Anticancer research | 28 | 29 | |
33 | 2019 | A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life | Chou, Wen Chi; Chen, Jen Shi; Hung, Chia Yen; Lu, Chang Hsien; YU-YUN SHAO ; Chiou, Tzeon Jye; Sung, Yung Chuan; Rau, Kun Ming; Yen, Chia Jui; Yeh, Su Peng; Liu, Ta Chih; Wu, Ming Fang; Lee, Ming Yang; Yu, Ming Sun; Hwang, Wen Li; Lai, Pang Yu; Chang, Cheng Shyong; Hsieh, Ruey Kuen | Supportive Care in Cancer | 11 | 8 | |
34 | 2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
35 | 2019 | Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study | Cho, Shih Feng; Rau, Kun Ming; YU-YUN SHAO ; Yen, Chia Jui; Wu, Ming Fang; Chen, Jen Shi; Chang, Cheng Shyong; Yeh, Su Peng; Chiou, Tzeon Jye; Hsieh, Ruey Kuen; Lee, Ming Yang; Sung, Yung Chuan; Lee, Kuan Der; Lai, Pang Yu; Yu, Ming Sun; Hwang, Wen Li; Liu, Ta Chih | Supportive Care in Cancer | 11 | 10 | |
36 | 2019 | Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment | LI-CHUN LU ; Lee, Yi Hsuan; Chang, Chun Jung; CHIA-TUNG SHUN ; Fang, Chih Yeu; YU-YUN SHAO ; TSUNG-HAO LIU ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver Cancer | 45 | 41 | |
37 | 2019 | Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management | O'Brien, Tony; Ahn, Jin Seok; Chye, Richard; Le, Brian; Lu, Henry; Olarte, Gabriel; Palladini, Mariana; Salti, Amar; YU-YUN SHAO ; Yaakup, Hayati; Buemio, Kristal Cielo; Colin, Consuelo Gutierrez; Hadjiat, Yacine | Journal of Opioid Management | 2 | 0 | |
38 | 2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 46 | 44 | |
39 | 2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 58 | 58 | |
40 | 2019 | Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma | YU-YUN SHAO ; Yong-Shi Li; Hung-Wei Hsu; Hang Lin; Han-Yu Wang; Rita Robin Wo; ANN-LII CHENG ; CHIH-HUNG HSU | Cancers | 14 | 14 | |
41 | 2018 | Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS | Chiu, Huai Hsuan; Liao, Hsiao Wei; YU-YUN SHAO ; YEN-SHEN LU ; CHING-HUNG LIN ; Tsai, I. Lin; CHING-HUA KUO | Analytica Chimica Acta | 49 | 45 | |
42 | 2018 | A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma | SHIH-HUNG YANG ; YU-YUN SHAO ; CHIA-CHI LIN ; SUNG-HSIN KUO ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 3 | 2 | |
43 | 2018 | Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure | TSUNG-HAO LIU ; CHIH-HUNG HSU ; YU-YUN SHAO | Liver Cancer | 3 | 2 | |
44 | 2017 | Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells | YU-YUN SHAO ; MIN-SHU HSIEH ; Wang, Han Yu; Li, Yong Shi; Lin, Hang; Hsu, Hung Wei; Huang, Chung Yi; CHIH-HUNG HSU ; ANN-LII CHENG | Oncotarget | 12 | 9 | |
45 | 2017 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy | YU-YUN SHAO ; BANG-BIN CHEN ; DA-LIANG OU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; Wang, M. J.; ANN-LII CHENG ; CHIUN HSU | Alimentary Pharmacology and Therapeutics | 10 | 8 | |
46 | 2017 | Right or left? Side selection for a totally implantable vascular access device: A randomised observational study | WEN-YING LIN ; CHIH-PENG LIN ; CHIH-HUNG HSU ; Lee, Ying Hui; Lin, Yi Ting; Hsu, Meng Chi; YU-YUN SHAO | British Journal of Cancer | 13 | 10 | |
47 | 2017 | Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan | Shen, Wen Chi; Chen, Jen Shi; YU-YUN SHAO ; Lee, Kuan Der; Chiou, Tzeon Jye; Sung, Yung Chuan; Rau, Kun Ming; Yen, Chia Jui; Liao, Yu Min; Liu, Ta Chih; Wu, Ming Fang; Lee, Ming Yang; Yu, Ming Sun; Hwang, Wen Li; Lai, Pang Yu; Chang, Cheng Shyong; Chou, Wen Chi; Hsieh, Ruey Kuen | Journal of Pain and Symptom Management | 19 | 17 | |
48 | 2017 | Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study | YI-HSIN LIANG ; YU-YUN SHAO ; Chen, Ho Min; ANN-LII CHENG ; Lai, Mei Shu; KUN-HUEI YEH | Anticancer Research | 10 | 11 | |
49 | 2017 | National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients | YU-YUN SHAO ; Hsiue E.H.-C.; CHIH-HUNG HSU ; CHIEN-AN YAO ; Chen H.-M.; Lai M.-S.; ANN-LII CHENG | Oncologist | 21 | 17 | |
50 | 2017 | Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study | LI-CHUN LU ; PEI-JER CHEN ; Yeh Y.-C.; CHIH-HUNG HSU ; Chen H.-M.; Lai M.-S.; YU-YUN SHAO ; ANN-LII CHENG | Anticancer Research | 15 | 16 | |
51 | 2017 | High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG ; CHIH-HUNG HSU | Japanese Journal of Clinical Oncology | 35 | 31 | |
52 | 2017 | Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer | YI-HSIN LIANG ; Wei, C. H.; Hsu, W. H.; YU-YUN SHAO ; Lin, Y. C.; Chou, P. C.; ANN-LII CHENG ; KUN-HUEI YEH | Support Care Cancer | 10 | 10 | |
53 | 2017 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) | Abou-Alfa G.K.; Yen C.-J.; CHIH-HUNG HSU ; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; YU-YUN SHAO ; ZHONG-ZHE LIN ; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG ; Carrasquilo J.A. | Cancer Chemotherapy and Pharmacology | 20 | 19 | |
54 | 2016 | Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma | Lin H.-H.; Feng W.-C.; LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer letters | 37 | 39 | |
55 | 2016 | Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression | CHIUN HSU ; LIANG-IN LIN ; Cheng, Yu-Che; Feng, Zi-Rui; YU-YUN SHAO ; ANN-LII CHENG ; DA-LIANG OU | Clinical Cancer Research | 43 | 41 | |
56 | 2016 | Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; Lee, Ying-Hui; CHIH-HUNG HSU ; ANN-LII CHENG | J. Gastroenterol. Hepatol. | 26 | 24 | |
57 | 2016 | Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice | YI-HSIN LIANG ; YU-YUN SHAO ; BIN-CHI LIAO ; Lee, Ho-Sheng; CHIH-HSIN YANG ; Chen, Ho-Min; CHUN-JU CHIANG ; ANN-LII CHENG ; Lai, Mei-Shu | Journal of Cancer | 8 | 7 | |
58 | 2016 | Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study | KUO-HSING CHEN ; YU-YUN SHAO ; Chen H.-M.; Lin Y.-L.; ZHONG-ZHE LIN ; Lai M.-S.; ANN-LII CHENG ; KUN-HUEI YEH | BMC Cancer | 41 | 39 | |
59 | 2016 | Key opioid prescription concerns in cancer patients: A nationwide study | CHIH-PENG LIN ; CHIH-HUNG HSU ; WEN-MEI FU ; Chen, H. M.; Lee, Y. H.; Lai, M. S.; YU-YUN SHAO | Acta Anaesthesiologica Taiwanica | 10 | 0 | |
60 | 2015 | Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer | Yeh C.-C.; CHIH-HUNG HSU ; YU-YUN SHAO ; Ho W.-C.; MONG-HSUN TSAI ; Feng W.-C.; LU-PING CHOW | Molecular and Cellular Proteomics | 55 | 50 | |
61 | 2015 | High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib | Lin T.-H.; YU-YUN SHAO ; Chan S.-Y.; Huang C.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Clinical Cancer Research | 78 | 78 | |
62 | 2015 | Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma | BIN-CHI LIAO ; YU-YUN SHAO ; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN ; Kuo R.N.; Lai C.-L.; KUO-HSING CHEN ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Clinical Lung Cancer | 11 | 8 | |
63 | 2015 | The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia | HUNG-YANG KUO ; ZHONG-ZHE LIN ; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO ; CHIUN HSU ; WEN-FANG CHENG ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Oncologist | 10 | 10 | |
64 | 2015 | Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? | YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG | World Journal of Gastroenterology | 36 | 38 | |
65 | 2015 | Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan | YU-YUN SHAO ; CHIH-HUNG HSU ; KUN-HUEI YEH ; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; ZHONG-ZHE LIN ; ANN-LII CHENG ; Lai M.-S. | Clinical Colorectal Cancer | 35 | 32 | |
66 | 2015 | Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials | YU-YUN SHAO ; Shau, W.-Y.; Chan, S.-Y.; LI-CHUN LU ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology (Switzerland) | 30 | 29 | |
67 | 2015 | Young patients with colorectal cancer have increased risk of second primary cancers | YI-HSIN LIANG ; YU-YUN SHAO ; Chen H.-M.; Lai C.-L.; ZHONG-ZHE LIN ; Kuo R.N.; ANN-LII CHENG ; KUN-HUEI YEH ; Lai M.-S. | Japanese Journal of Clinical Oncology | 12 | 11 | |
68 | 2014 | β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Lee Y.-H.; MIN-SHU HSIEH ; Hsiao C.-H.; Lin H.-H.; HSIANG-FONG KAO ; Ma Y.-Y.; Yen F.-C.; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology (Switzerland) | 25 | 24 | |
69 | 2014 | Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases | YU-YUN SHAO ; MING-CHIH HO ; ANN-LII CHENG ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 3 | 3 | |
70 | 2014 | Clinical activity of metronomic chemotherapy in liver cancers | YU-YUN SHAO ; ANN-LII CHENG ; CHIH-HUNG HSU | Metronomic Chemotherapy: Pharmacology and Clinical Applications | 0 | 0 | |
71 | 2014 | Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy | LI-CHUN LU ; YU-YUN SHAO ; Chan S.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | 10 | |
72 | 2014 | Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy | YU-YUN SHAO ; CHIH-HORNG WU ; LI-CHUN LU ; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; CHIH-HUNG HSU ; ANN-LII CHENG | Journal of Hepatology | 46 | 48 | |
73 | 2014 | Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer | KUO-HSING CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; KUN-HUEI YEH ; ANN-LII CHENG ; Lai M.-S. | Oncologist | 24 | 19 | |
74 | 2013 | Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size | ZHONG-ZHE LIN ; Shau W.-Y.; CHIUN HSU ; YU-YUN SHAO ; Yeh Y.-C.; Kuo R.N.-C.; CHIH-HUNG HSU ; CHIH-HSIN YANG ; ANN-LII CHENG ; Lai M.-S. | PLoS ONE | 26 | 24 | |
75 | 2013 | Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Kuo R.N.C.; ZHONG-ZHE LIN ; Yeh Y.-C.; Shau W.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG ; Lai M.-S. | Cancer | 11 | 11 | |
76 | 2013 | Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer | YU-YUN SHAO ; Shau W.-Y.; ZHONG-ZHE LIN ; Chen H.-M.; Kuo R.; CHIH-HSIN YANG ; Lai M.-S. | European Journal of Cancer | 20 | 18 | |
77 | 2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 40 | 41 | |
78 | 2013 | The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; Chang Y.-L.; Huang C.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology (Switzerland) | 5 | 5 | |
79 | 2013 | A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy | YU-YUN SHAO ; PO-CHIN LIANG ; YAO-MING WU ; Huang C.-C.; KAI-WEN HUANG ; CHIA-HSIEN CHENG ; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; ZHONG-ZHE LIN | Liver International | 15 | 15 | |
80 | 2012 | Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems | YU-YUN SHAO ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | British Journal of Cancer | 26 | 26 | |
81 | 2012 | Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy | YU-YUN SHAO ; Huang C.-C.; Lin S.-D.; CHIH-HUNG HSU ; ANN-LII CHENG | Clinical Cancer Research | 39 | 37 | |
82 | 2012 | Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study | ZHONG-ZHE LIN ; Shau W.-Y.; YU-YUN SHAO ; Yang Y.-Y.; Kuo R.N.-C.; CHIH-HSIN YANG ; Laie M.-S. | Oncologist | 11 | 9 | |
83 | 2012 | Survival of patients with small cell lung carcinoma in Taiwan | Kuo Y.-H.; ZHONG-ZHE LIN ; Yang Y.-Y.; YU-YUN SHAO ; Shau W.-Y.; Kuo R.N.C.; CHIH-HSIN YANG ; Lai M.-S. | Oncology | 22 | 18 | |
84 | 2012 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Lee, Kuan-Der; Hsiao, Chi-Huang; YEN-SHEN LU ; Huang, Chien-Chung; YING-CHUN SHEN ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 26 | 25 | |
85 | 2012 | Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer | LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; CHIUN HSU ; WEN-FANG CHENG ; YU-LIN LIN ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 0 | ||
86 | 2012 | Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma | Shau W.-Y.; YU-YUN SHAO ; Yeh Y.-C.; ZHONG-ZHE LIN ; Kuo R.; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; Lai M.-S. | Oncologist | 32 | 32 | |
87 | 2012 | Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma | YU-YUN SHAO ; Chen C.-L.; MING-CHIH HO ; Huang C.-C.; Tu H.-C.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 9 | 10 | |
88 | 2012 | The impact of diabetes mellitus on prognosis of early breast cancer in Asia | WEI-WU CHEN ; YU-YUN SHAO ; Shau W.-Y.; ZHONG-ZHE LIN ; YEN-SHEN LU ; Chen H.-M.; Kuo R.N.C.; ANN-LII CHENG ; Lai M.-S. | Oncologist | 36 | 34 | |
89 | 2012 | Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy | ZHONG-ZHE LIN ; CHIUN HSU ; Hu F.-C.; YU-YUN SHAO ; DWANG-YING CHANG ; CHIH-HSIN YANG ; RUEY-LONG HONG ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncologist | 8 | 10 | |
90 | 2011 | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | YU-YUN SHAO ; ZHONG-ZHE LIN ; Chen T.-J.; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 17 | 17 | |
91 | 2011 | Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy | YU-YUN SHAO ; LI-CHUN LU ; ANN-LII CHENG ; CHIH-HUNG HSU | Oncologist | 34 | 28 | |
92 | 2011 | Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; PEI-JER CHEN ; ZHONG-ZHE LIN ; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | ||
93 | 2010 | Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; Huang C.; PO-CHIN LIANG ; ZHONG-ZHE LIN | Asia-Pacific Journal of Clinical Oncology | 29 | 29 | |
94 | 2010 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Ying-Chun Shen ; ZHONG-ZHE LIN ; PEI-JER CHEN ; YU-YUN SHAO ; Ding Y.-H.; CHIUN HSU ; ANN-LII CHENG | Journal of Hepatology | 110 | 103 | |
95 | 2010 | Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin | YU-YUN SHAO ; KUAN-TING KUO ; Hu F.-C.; YEN-SHEN LU ; CHIUN-SHENG HUANG ; JAU-YU LIAU ; Lee W.-C.; CHIUN HSU ; WEN-HUNG KUO ; KING-JEN CHANG ; CHING-HUNG LIN ; ANN-LII CHENG | Japanese Journal of Clinical Oncology | 28 | 24 | |
96 | 2010 | Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. | YU-YUN SHAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Discovery medicine | 13 | 12 | |
97 | 2010 | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer | 141 | 148 | |
98 | 2010 | Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma | YU-YUN SHAO ; RUEY-LONG HONG | Oral Oncology | 6 | 7 | |
99 | 2010 | Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions | YU-YUN SHAO ; Hu F.-C.; JIN-TUNG LIANG ; Chiu W.-T.; ANN-LII CHENG ; CHIH-HSIN YANG | Journal of the Formosan Medical Association | 27 | 23 | |
100 | 2009 | Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment | YU-YUN SHAO ; ZHONG-ZHE LIN ; PO-CHIN LIANG ; YU-WEN TIEN ; ANN-LII CHENG | Anticancer Research | 1 | 1 | |
101 | 2008 | Fatal thrombocytopenia after oxaliplatin-based chemotherapy | YU-YUN SHAO ; RUEY-LONG HONG | Anticancer Research | 19 | 20 |